Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/06/2003US20030207923 Treatment of autoimmune disease, inflammation and allergy; inhibits release of tumour necrosis factor
11/06/2003US20030207920 N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants
11/06/2003US20030207917 1,4-di-substituted piperidines, some of which have M2 selectivity even higher than that of 3-alpha-chloroimperialine for treating cognitive disorders such as Alzheimer's disease
11/06/2003US20030207914 For treatment of tumors and/or cancerous cell growth mediated by raf kinase
11/06/2003US20030207911 For treatment of disease associated with the adenosine A2 receptor such as Alzheimer's disease and Parkinson's disease
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207900 2-substituted amino-bicyclic pyridine and pyrimidine compounds; for treatment of inflammation, inflammatory bowel disease, Alzheimer's disease, Crohn's disease, multiple sclerosis and asthma
11/06/2003US20030207898 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders
11/06/2003US20030207897 Selective inhibitors of cyclooxygenase-2
11/06/2003US20030207896 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207892 Heterocyclic amines such as N-(Pyridin-4-yl)-(1-(4-fluoro-benzyl)indol-3-yl)glyoxylamide, used for prophylaxis of skin disorders, rheumatic diseases or arthritis
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207887 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
11/06/2003US20030207885 Nitrogen compounds such as 6-chloro-3-ethyl-2-(2-thiazol-2-yl -imidazol-1-ylmethyl)-imidazo(1,2-b)pyridazine used for prophylaxis of nervous system disorders
11/06/2003US20030207883 Indazole benzimidazole compounds
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207877 Pyridoquinoxaline antivirals
11/06/2003US20030207875 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
11/06/2003US20030207871 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207861 Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
11/06/2003US20030207859 Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
11/06/2003US20030207858 Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function.
11/06/2003US20030207852 Treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment.
11/06/2003US20030207847 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207844 Methods, compositions, and kits, are provided for the use of nitric oxide synthase inhibitors to prevent and reduce wrinkles.
11/06/2003US20030207841 Novel nucleoside and oligonucleotide analogues
11/06/2003US20030207451 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207380 For diagnosis and treatment of estrogenic disorder of mutant ER alpha
11/06/2003US20030207291 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby
11/06/2003US20030207262 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
11/06/2003US20030206971 Aqueous acidulant part comprising an activator acid, a rheology modifier or a pseudoplastic thickener, a chlorine dioxide stable visual indicator system; alkali metal chlorite
11/06/2003US20030206963 Bone resorption suppressing agent
11/06/2003US20030206923 Combination of soybean, mushroom and mung bean provides phytoestrogens, beta-glucans, saponins, inositol hexaphosphate, and lectins.
11/06/2003US20030206911 Modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target
11/06/2003US20030206869 Delivery of antidepressants through an inhalation route
11/06/2003US20030206861 Uses of diterpenoid triepoxides as an antiproliferative agent
11/06/2003US20030206858 Metal complex-containing pharmaceutical agents
11/06/2003CA2484306A1 Prophylactic and therapeutic agent of diabetes mellitus
11/06/2003CA2484089A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483701A1 Constitutively active histamine h3 receptor mutants and uses thereof
11/06/2003CA2483557A1 Methods and compositions for treating, preventing or delaying onset of a neoplasm
11/06/2003CA2483525A1 Method of measuring neprilysin activity
11/06/2003CA2483515A1 Novel thiol derivative, method for producing the same and use thereof
11/06/2003CA2483505A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483431A1 Alternatively spliced nucleic acid molecules
11/06/2003CA2483340A1 Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
11/06/2003CA2483336A1 Method and apparatus for ultrasound treatment of connective tissue
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483306A1 Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
11/06/2003CA2483270A1 Treatment of alpha-galactosidase a deficiency
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483155A1 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
11/06/2003CA2483106A1 Decoys for treating and/or preventing th2 cytokine-related allergic diseases, gata3 mutant proteins and, pharmaceutical compositions comprising the decoys and the proteins
11/06/2003CA2483093A1 Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2482996A1 Vitamin d3 upregulated protein 1 treats post-infarct myocardial ischemia
11/06/2003CA2482711A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003CA2482455A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003CA2482432A1 Method of preparing amine stereoisomers
11/06/2003CA2481449A1 Method and compositions for identifying anti-hiv therapeutic compounds
11/06/2003CA2481324A1 [1,4]diazocino [7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents
11/06/2003CA2481285A1 Non nucleoside reverse transcriptase inhibitors
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/05/2003EP1359215A1 Soya cell strains with high isoflavone content
11/05/2003EP1359159A2 Analogues of GLP-1
11/05/2003EP1359147A1 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same
11/05/2003EP1358889A1 Medicinal compositions for treating lower uropathy
11/05/2003EP1358883A1 Re-epithelializing pharmaceutical compositions containing xanthan gum
11/05/2003EP1358879A1 Antilipemic agents
11/05/2003EP1358869A1 Biologically active compounds for the modificaton of bodily odours
11/05/2003EP1358868A2 Cosmetic composition for increasing hair growth and/or for preventing or delaying hair loss
11/05/2003EP1358354A1 Method for identifying compounds modulating reverse cholesterol transport
11/05/2003EP1358348A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/05/2003EP1358336A2 Human serine-threonine kinase
11/05/2003EP1358334A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
11/05/2003EP1358332A2 A serpin in bifidobacteria
11/05/2003EP1358330A2 Transporters and ion channels
11/05/2003EP1358328A2 Regulation of human serotonin-like g protein-coupled recepter
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358316A1 Enteric nervous system derived stem and progenitor cells and uses thereof
11/05/2003EP1358209A2 Crystallization of igf-1
11/05/2003EP1358206A2 Peptide-based compounds
11/05/2003EP1358189A1 Process for the preparation of a pyrazolo 4,3-d]pyrimidine derivative
11/05/2003EP1358187A2 Naphthyridine derivatives
11/05/2003EP1358184A1 Substituted alkylamine derivatives and methods of use
11/05/2003EP1358183A2 Cysteine protease inhibitors
1 ... 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 ... 1564